Gabelli Funds’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Gabelli Funds’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-181,442	Closed	-$4.19M	–	1457
2020 Q4	$4.19M	Buy	+181,442	New	+$2.3M	0.03%	525

Gabelli Funds's PRVL Position: Q1 2021 in Review

Gabelli Funds sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 181,442 shares — an estimated $4.19M sold.

Gabelli Funds first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $4.19M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Gabelli Funds reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Gabelli Funds sold 181,442 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $4.19M.
Gabelli Funds first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Gabelli Funds's Prevail Therapeutics Inc. Common Stock position peaked at $4.19M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Gabelli Funds's 13F filing for Q1 2021, filed 14 May 2021.